
|Videos|July 1, 2022
Dr. Brugarolas on unmet needs in the renal cell carcinoma treatment paradigm
Author(s)Urology Times staff
Understanding the mechanisms of treatment resistance is among the areas of unmet need, says James Brugarolas, MD, PhD.
Advertisement
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, lists several areas of unmet need in the treatment paradigm for patients with renal cell carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












